Home » Business News » 2012 » October » October 25, 2012

PropThink: Abraxane Data, Earnings Release Rally CELG; Back to Highs by Year End?

October 25, 2012 -

By Jake King
In separate press releases on Thursday morning, Celgene (NASDAQ:CELG) reported 3Q results and announced that Abraxane demonstrated a statistically significant improvement in Progression Free Survival (PFS) in its latest Phase 3 study for advanced melanoma. Celgene reported revenue of $1.42B and adjusted, diluted earnings of $1.29 per share ($561M non-GAAP net income), a consensus beat for the company as estimates placed revenue at $1.41B and adjusted EPS at $1.27. Celgene reported third quarter net income (GAAP) of $424 million or $0.97 per diluted share. The company raised its adjusted EPS outlook for FY2012 to $4.85-$4.90 from $4.80-$4.85.
Abraxane is already available as a treatment for metastatic breast cancer and received FDA approval for advanced non-small cell lung cancer in combination with carboplatin just this month. Today's news is another step towards adding a third indication to the versatile chemotherapy agent. The trial met its primary endpoint - improvement in PFS - and showed a favorable trend towards overall survival, its secondary endpoint. In chemotherapy-naive patients, Abraxane demonstrated a PFS of 4.8 months, nearly doubling the 2.5 month PFS in the control arm, patients treated with standard dacarbazine chemotherapy. Celgene is also pursuing a metastatic pancreatic cancer indication, with a Phase 3 trial set to report data in the fourth quarter. Management has guided for Abraxane sales, including all potential indications, of over $1B by 2015. Continue reading this article by clicking here.
""Abraxane Data, Earnings Release Rally CELG; Back to Highs by Year End?"" at
About PropThink
PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued. We offer daily market coverage, weekly feature stories, and a newsletter to investors who subscribe on To learn more, follow us on Twitter or visit us at
You should assume that as of the publication date of any report or letter, PropThink, LLC and persons or entities with whom it has relation ships (collectively referred to as ""PropThink"") has a position in all stocks (and/or options of the stock) covered herein that is consistent with the position set forth in our research report. Following publication of any report or letter, PropThink intends to continue transacting in the securities covered herein, and we may be long, short, or neutral at any time hereafter regardless of our initial recommendation. To the best of our knowledge and belief, all information contained herein is accurate and reliable, and has been obtained from public sources we believe to be accurate and reliable, and not from company insiders or persons who have a relationship with company insiders. PropThink was not compensated to publish this article. Our full disclaimer is available at

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: PropThink via Thomson Reuters ONE


Copyright 2012 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

ACN Newswire

Comment on this story